For individuals and entities involved in projects under Subprogram 4—Support for National Authorities in Priority Areas of Health Research—we have prepared guidelines and answers to frequently asked questions. These materials provide practical information on the administration and financing of Subprogram 4 projects, making changes, reporting, and…
The best-rated projects completed in 2025 were presented by their researchers at the annual conference of the Agency for Health Research ČR , which took place on September 23rd at the premises of the 1st Faculty of Medicine, Charles University. The meeting was also attended by the Minister of Health, Adam Vojtěch, who…
The European Partnership for Personalized Medicine (EP PerMed) platform offers an easily accessible space for establishing new collaborations. Its goal is to connect researchers, clinicians, companies, patients, representatives of regulatory authorities, and other key stakeholders in the field of personalized medicine. This collaboration will create an international…
The Ministry of Health presents the results evaluation of the evaluation Reports on projects funded by the Ministry of Health ČR AZV ČR) that were completed in 2025. All evaluated projects were completed as of December 31, 2025, and were part of the VES 2020, VES 2021-J, and VES 2022-J calls for proposals. evaluation
The Ministry of Health (hereinafter referred to as “MoH”), pursuant to the Program to Support Applied Health Research for 2024–2030 (hereinafter referred to as “Program NW”), Subprogram 4: Support for National Authorities in Priority Areas of Health Research (hereinafter referred to as “Subprogram 4”) and in accordance with the Act…
On July 15, the Ministry of Health presented the first National Strategy for evaluation Clinical evaluation Medicinal Products in ČR (NS KHLP 2035) at a press conference. This is phase significant phase developing a modern, transparent, and competitive environment for conducting clinical evaluation
On July 1, 2026, the European Partnership for Rare Diseases (ERDERA) announced a new call for proposals, the Clinical Trial Call 2026 (ECTC). The call supports transnational early-phase interventional clinical trials in the field of rare diseases that are conducted in accordance with the principles of Good Clinical Practice (Good Clinical…
Effective June 16, 2026, Ing. Iva Škach Vrbíková was ČR Director of the Office of the ČR Health Research Agency. She succeeds Bc. Martin Suchý, who has left the agency. Ing. Iva Škach Vrbíková previously served as…
Czech health research achieves above-average results in international comparisons, even though the government invests significantly less in it than most developed European countries. This is shown by an interim evaluation of the Program to Support Applied Health Research for 2024–2030, which was conducted for the Health Research Agency…
On June 3, 2026, the European Rare Diseases Research Alliance (ERDERA) published a notice regarding the new Clinical Trial Call 2026 (ECTC), which will be launched on July 1, 2026. This call will support transnational Phase I and Phase I/II interventional clinical trials…